AstraZeneca
A global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $1.4b | Post IPO Debt |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 41 % | 19 % | 3 % | 18 % | 7 % | 6 % | 6 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 20 % | 21 % | 30 % | 32 % | 34 % | 37 % | 38 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 7 % | 13 % | 13 % | 17 % | 20 % | 21 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 26 % | 22 % | 24 % | 25 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
AstraZeneca is a leading global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates in three main therapy areas: Oncology (cancer treatment), Cardiovascular, Renal & Metabolism (heart, kidney, and metabolic diseases), and Respiratory & Immunology (lung and immune system diseases). AstraZeneca serves a diverse range of clients, including healthcare providers, hospitals, and patients worldwide.
The company operates in the highly competitive pharmaceutical market, which is driven by innovation and regulatory compliance. AstraZeneca's business model revolves around extensive research and development (R&D) to create new drugs and therapies. They invest heavily in scientific research to discover new treatments and improve existing ones. Once a drug is developed, it goes through rigorous clinical trials and regulatory approvals before it can be marketed and sold.
AstraZeneca makes money primarily through the sale of its prescription medicines. The company also engages in strategic partnerships and collaborations with other organizations to enhance its research capabilities and expand its product portfolio. For instance, their Open Innovation program allows them to share compounds, tools, and technologies with the scientific community to accelerate drug discovery and development.
Additionally, AstraZeneca has a network called A.Catalyst Network, which consists of over 20 health innovation hubs around the world. These hubs foster collaboration and innovation by connecting physical locations and virtual partnerships. This network helps AstraZeneca stay at the forefront of scientific advancements and bring new treatments to market more efficiently.
In summary, AstraZeneca is a forward-thinking biopharmaceutical company dedicated to advancing healthcare through innovative research and strategic collaborations. They serve a global market with a focus on developing treatments for serious diseases, making money through the sale of their medicines and partnerships.
Keywords: Biopharmaceutical, Oncology, Cardiovascular, Respiratory, Innovation, Research, Development, Prescription Medicines, Collaboration, Global Market.
Tech stack
Investments by AstraZeneca
Edit
